

CLAIMS

1. Use of a polymer comprising an effective quantity of disaccharide units each composed of an N-acetyl-D-glucosamine structure molecule bonded by an O-glycoside β 1,4 bond with a glucuronic acid structure 5 molecule for the production of a medicinal product intended to induce or stimulate the differentiation of cells chosen from the group composed of leukaemic cells and CD14 $^{-}$ CD15 $^{-}$ strain cells.

2. Use according to claim 1, characterised in that 10 said effective quantity is equivalent to a number of disaccharide units greater than or equal to 3.

3. Use according to any of the above claims, characterised in that said effective quantity is equivalent to a number approximately between 3 and 10. 15

4. Use according to any of the above claims, characterised in that said effective quantity is equivalent to a number approximately between 10 and 100.

5. Use according to any of the above claims, 20 characterised in that said polymer is chosen from the

group composed of hyaluronic acid and the fragments of this acid.

6. Use according to any of the above claims, characterised in that said polymer is used for the 5 production of said medicinal product at a unit dose between approximately 1 and 10 mg/kg inclusive, advantageously between approximately 2 and 5 mg/kg, particularly of the order of approximately 3 mg/kg.

7. Use according to any of the above claims, 10 characterised in that said polymer is used in the form of solution, preferably solution for injection by the intravenous route.

8. Use according to any of the above claims, characterised in that it also comprises the use of an 15 adjuvant compound capable of stimulating the bonding of said polymer with its cell target, such as an anti-CD44 antibody, or a fragment of such an antibody.

9. Use according to any of the above claims, characterised in that it also comprises the use of a 20 compound capable of preventing the bonding of said polymer with an undesired cell target, in particular, an anti-ICAM1 monoclonal antibody or a fragment of such an antibody.

10. Use according to any of the above claims, 25 characterised in that said leukaemic cells are AML1/2 and/or AML3 and/or AML4 and/or AML5 and/or AML6 and/or AML7 acute myeloblastic leukaemia cells.

11. Medicinal product intended to induce or stimulate the differentiation of CD14⁻ CD15⁻ strain 30 cells and/or leukaemic cells and AML blasts in particular, characterised in that it comprises an

effective quantity of disaccharide units each composed of an N-acetyl-D-glucosamine structure molecule bonded by an O-glycoside β 1,4 bond with a glucuronic acid structure molecule.

DRAFT EDITION